The goal of the study was to create a proliposomal version of the NSAID medication flurbiprofen. Proliposomes were made utilizing the vacuum rotatory evaporator thin-film hydration approach, which included varying amounts of mannitol, phospholipid and cholesterol. A preformulation study was conducted to produce stable liposomes free of aggregation, fusion and sedimentation. Thin-film hydration was used to manufacture flurbiprofen proliposomes, which were found to be effective in producing liposomes that did not aggregate. The amount of cholesterol, phospholipid and aspartame was crucial for proliposome production and stabilization. Liposome vesicle size and dispersion were critical parameters for optimal results. A positive association was found between phospholipid and cholesterol, indicating that an increase in phospholipid and cholesterol content increased the size of the vesicles. Entrapment efficiency was found to be a crucial factor in liposomes, with entrapment efficiency ranging from 85.12 to 96.5%. Formulations F4-F9 exhibited the highest vesicle size and entrapment effectiveness, with flurbiprofen content ranging from 86.4% to 96.8%. Formulations F4, F1, F5 and F6 had peak drug content. The percentage yield results varied between 86.5±0.265 and 95.4±0.221 percent. When compared to pure medication, the in-vitro experiments showed that proliposomal gel formulation displays enhanced skin permeability exhibiting sustain release.
Loading....